PRESTRELSKI STEVEN (Chief Scientific Officer) sold 1.9% of their position (11.23K shares) of XERIS BIOPHARMA HOLDINGS, INC. on the open market
Open‑market sale worth $27.2K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 2/24/2022ACC: 0001867096-22-000025
Officer· Chief Scientific Officer
Since Oct 2021
-11.23K
Net shares
Net seller
$27.2K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
11.23K acquired · 22.46K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+11.23K
Price / share
$0.69
Trade value
$7.75K
% of position
2.0%
2/22/2022
569.78K→581.01K
Common Stock
Direct
Shares
−11.23K
Price / share
$2.42
Trade value
$27.16K
% of position
1.9%
2/22/2022
581.01K→569.78K
Total
Net shares
+0.00
Net value
-$19.41K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 2/22/2022 | M · Option Exercise | +11.23K | $0.69 | $7.75K | 2.0% | 569.78K | 581.01K |
| Common Stock Direct | 2/22/2022 | S · Sale | −11.23K | $2.42 | $27.16K | 1.9% | 581.01K | 569.78K |
| Total | +0.00 | -$19.41K | ||||||
Derivative Transactions1
Stock Option (Right to Buy)
Direct
Converts to
Common Stock
11.23K shares
Shares
−11.23K
Strike price
0.69
Held after
0.00
Exercisable
—
2/22/2022
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Stock11.23K shares | 2/22/2022 | M · Option Exercise | −11.23K | 0.69 | — | 0.00 |